Charles River Laboratories Inter (NYSE: CRL) has reported earnings for its first fiscal quarter (ending March 31) of $1.31 versus $2.02 for the same period a year ago — a decline of -35%. This result fell short of the consensus estimate of $2.51 by $-1.20. For the latest four quarters through March 31, E.P.S. were $8.55 compared to $9.75 a year ago — a decline of -12%.
Recent Price Action
Charles River Laboratories Inter (NYSE: CRL) stock closed at $230.09 on 5/9/24 after a decline of -2.2%. Moreover, this decline was accompanied by exceptionally high trading volume at 202% of normal. The stock has declined -1.1% during the last week but has been exceptionally strong relative to the market over the last nine months.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to be above the cost of capital, CRL is expected to continue to be an important Value Builder.
Charles River Laboratories Inter has a current Value Trend Rating of B (Positive). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing inconsistent signals. Charles River Laboratories Inter has a neutral Appreciation Score of 50 but a good Power Rating of 81, triggering the Positive Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of B. This review will be completed in the next several days.
Be the first to comment